Skip to main content
OpenTrials
Completed

NCT Number: NCT02904395

Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth

Given the 100 fold increase of the incidence of Pompe's disease in Western French Guiana, the objective of the present study is to implement systematic screening in newborns in French Guiana in order to start treatment before the muscular and cardiac symptoms appear.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • newborn

Exclusion criteria

  • parent refusal

Treatment and study plan

observational (no intervention)

Other

Primary outcomes

  1. acid maltase activity

    Time frame: At birth

    The acid maltase enzyme activity is evaluated just after birth. If it is abnormal then PCR allows to identify signature mutations.

  2. Signature mutation for pompe's disease

    Time frame: At birth

    The acid maltase enzyme activity is evaluated just after birth. If it is abnormal then PCR allows to identify signature mutations.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Cayenne

Other

Registry information

Acronym: DEPIPOMP1

Important dates

Study start
2014
Primary completion
2014
Study completion
2015
First posted
Sep 19, 2016
Registry last updated
Sep 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.